J Surg Oncol

• 

  Publication Venue For

  • Response to Letter to the Editor: "The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma"..  120:566. 2019
  • The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma..  120:132-141. 2019
  • Deficiencies in postoperative surveillance for veterans with gastrointestinal cancer..  119:273-277. 2019
  • Updates in adjuvant systemic therapy for melanoma..  119:222-231. 2019
  • A preoperative prognostic model to predict surgical success in patients with perihilar cholangiocarcinoma..  118:469-476. 2018
  • Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma?.  117:1584-1588. 2018
  • Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: Should lymph node retrieval guidelines be altered?.  117:1708-1715. 2018
  • Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential..  117:634-643. 2018
  • Transected thin melanoma: Implications for sentinel lymph node staging..  117:567-571. 2018
  • Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes..  116:969-982. 2017
  • Perioperative fluid and hemodynamic management within an enhanced recovery pathway..  116:592-600. 2017
  • Recurrence patterns following irreversible electroporation for hepatic malignancies..  115:704-710. 2017
  • Evolving application of minimally invasive cancer operations at a tertiary cancer center..  115:365-370. 2017
  • Socioeconomic disparities, financial toxicity, and opportunities for enhanced system efficiencies for patients with cancer..  115:250-256. 2017
  • Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy..  113:477-484. 2016
  • Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma..  113:188-193. 2016
  • Neoadjuvant use of ipilimumab in locally advanced melanoma..  112:841-843. 2015
  • Analysis of perioperative radiation therapy in the surgical treatment of primary and recurrent retroperitoneal sarcoma..  112:352-358. 2015
  • Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer..  112:46-50. 2015
  • Impact of delayed lymphoscintigraphy for sentinel lymphnode biopsy for breast cancer..  111:931-934. 2015
  • Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy..  111:740-745. 2015
  • Outcomes following splenectomy in patients with myeloid neoplasms..  111:389-395. 2015
  • Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma..  110:682-688. 2014
  • Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis..  110:575-584. 2014
  • Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma..  110:412-415. 2014
  • Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: defining quality for pancreaticoduodenectomy..  110:400-406. 2014
  • Breast conservation: is the survival better for mastectomy?.  110:58-61. 2014
  • Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy..  109:740-745. 2014
  • Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times..  109:533-541. 2014
  • Assessment of multimodality therapy use for extremity sarcoma in the United States..  109:395-404. 2014
  • Partnering with engaged patients accelerates research..  109:504-505. 2014
  • Isolated limb infusion as a model to test new agents to treat metastatic melanoma..  109:357-365. 2014
  • Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature..  109:28-30. 2014
  • Intraoperative fluid management and complications following pancreatectomy..  107:529-535. 2013
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy..  107:307-311. 2013
  • Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease..  106:953-958. 2012
  • Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database..  106:357-362. 2012
  • Effect of surgeon specialization on long-term survival following colon cancer resection at an NCI-designated cancer center..  106:219-223. 2012
  • Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer..  106:24-30. 2012
  • Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?.  106:111-118. 2012
  • Molecular staging individualizing cancer management..  105:468-474. 2012
  • Effect of intra-operative fluid volume on peri-operative outcomes after pancreaticoduodenectomy for pancreatic adenocarcinoma..  105:81-84. 2012
  • Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma..  105:15-20. 2012
  • Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study..  102:565-570. 2010
  • Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival..  100:144-148. 2009
  • Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center..  100:8-12. 2009
  • A rationale for the targeted treatment of oligometastases with radiotherapy..  98:202-206. 2008
  • Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. 2017